Compare Walt Disney Co (DIS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Viatris Inc — how do they compare? Walt Disney Co trades at $108.05 (market cap $184.79B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Walt Disney Co is far larger — about 9.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Viatris Inc for 57 Days on average.
| DIS | VTRS | |
|---|---|---|
Market Cap | $184.79B | $20.03B |
Volume | 13,033,550 | 14,109,977 |
Sector | Media | Health |
52-Week High | $116.65 | $18.27 |
52-Week Low | $92.40 | $9.74 |
Typical Hold Time | 199 Days | 57 Days |
Enterprise Value | $225.65B | $32.15B |
Dividend Yield | 1.4% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.21% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue grew to $94.43B in 2025, with net income surging to $12.40B, though free cash flow faces pressure from increased investments. The stock remains below the analyst consensus price target of $125.67, indicating potential upside.
The outlook is positive with strong fundamentals and analyst support, but risks include streaming competition and high capital expenditures. Investment opportunity lies in execution of the $60B parks pipeline and streaming margin expansion, balanced against macroeconomic sensitivity and execution risks.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
